RESEARCH AND EDUCATION DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
Dihexa, also called PNB-0408, is an angiotensin IV-derived experimental compound examined in animal neuroscience research. A mouse study reported changes in learning and inflammatory markers, while a rat study found no protection against the deficits produced by a particular neurotoxin. The evidence also includes a retracted mechanism paper and a separate development paper carrying a notice of concern. A responsible account must distinguish these publication issues from the remaining experiments and avoid presenting Dihexa as an established human cognitive enhancer. [1–4]
WHAT IS DIHEXA?
Dihexa is a modified compound related to the angiotensin IV research program, rather than native angiotensin IV itself. The 2024 rat study identifies it as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide and uses the designation PNB-0408. [1]
This distinction matters when reading studies. Results for a naturally occurring peptide, a related analogue, or another compound in the same development program do not automatically establish the activity of Dihexa. The tested material must be identified before its findings can be applied to a research question.
WHY DO THE JOURNAL NOTICES MATTER?
A 2014 paper on angiotensin IV-derived peptides linked their reported effects on cognition and synapse formation to the hepatocyte growth factor/c-Met system. A formal retraction notice for that paper was published in 2025. It should not be presented as reliable affirmative evidence that Dihexa's proposed mechanism has been established. [2]
Separately, the journal published a 2021 notice of concern concerning a 2013 paper on metabolically stabilized angiotensin IV analogues. A notice of concern and a retraction are different editorial actions; they should be identified accurately. [3]
These notices do not, by themselves, determine the validity of every other experiment involving Dihexa. They do require removing confident claims that rest on the affected publications and assessing other studies on their own methods and results.
WHAT DID THE APP/PS1 MOUSE STUDY REPORT?
Sun and colleagues studied Dihexa in APP/PS1 mice, an experimental model used in Alzheimer's-related research. Their 2021 report described improved performance in a spatial-learning task, changes in neuronal and synaptic markers, and reduced activation of inflammatory cells in brain tissue. [4]
The researchers also reported involvement of the PI3K/AKT signaling pathway. A PI3K inhibitor reversed several anti-inflammatory and anti-apoptotic findings, supporting a role for that pathway under the tested conditions. This experiment does not independently establish the proposed direct interaction between Dihexa and hepatocyte growth factor. [4]
A behavioral result in genetically modified mice is not evidence of improved memory or dementia treatment in people. Tissue markers and signaling measurements help investigate mechanisms, but they do not replace human functional outcomes or clinical safety assessment.
WHAT DID THE HUNTINGTON'S-DISEASE-LIKE RAT STUDY FIND?
A 2024 study randomized 40 male rats among control, neurotoxin, and neurotoxin-plus-PNB-0408 groups. Researchers measured body weight, movement, and cognitive performance over five weeks in a model using 3-nitropropionic acid. [1]
PNB-0408 did not protect against the deficits caused by that toxin. The result should be included alongside favorable experiments rather than omitted from an evidence summary. It also does not prove that every other model must produce the same result. [1]
Different disease models ask different questions. An intervention can behave differently when the underlying injury, species, exposure, or measurement changes. Those differences are a reason for careful comparison and replication, rather than a basis for claiming universal neuroprotection.
WHAT CAN THE CURRENT EVIDENCE SUPPORT?
The animal studies reviewed here support a limited account of experimental findings, including a negative result. They do not establish benefits for human attention, memory, dementia, or recovery from brain injury. They also do not provide a basis for claims that Dihexa is a certain number of times more effective than a natural growth factor in people.
For research interpretation, publication status is as important as the abstract's headline. Readers should check whether a cited paper remains part of the reliable evidence base, whether the experiment actually tested Dihexa, and whether the claimed outcome matches what was measured. Separately supplied materials require their own identity and quality verification; a publication cannot certify a particular vial.
REFERENCES
Study and notice titles below are shortened for readability; each link identifies the original record.
[1] Wells RG, Azzam AF, Hiller AL, Sardinia MF. Effects of an angiotensin IV analog on 3-nitropropionic acid-induced Huntington's-disease-like symptoms in rats. Journal of Huntington's Disease. 2024;13(1):55–66.
https://doi.org/10.3233/JHD-231507
[2] Benoist CC, Kawas LH, Zhu M, et al. Retraction notice for the 2014 paper on angiotensin IV-derived peptides and the hepatocyte growth factor/c-Met system. Journal of Pharmacology and Experimental Therapeutics. 2025;392(4):103567.
https://doi.org/10.1016/j.jpet.2025.103567
[3] Notice of concern concerning McCoy and colleagues' 2013 evaluation of metabolically stabilized angiotensin IV analogues. Journal of Pharmacology and Experimental Therapeutics. 2021;378(3):313.
https://doi.org/10.1124/jpet.112.199497concern
[4] Sun X, Deng Y, Fu X, Wang S, Duan R, Zhang Y. AngIV-analog Dihexa and cognitive impairment in APP/PS1 mice: PI3K/AKT pathway research. Brain Sciences. 2021;11(11):1487.
https://doi.org/10.3390/brainsci11111487